Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof

The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T- cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 15. Dez. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

GARRETT-THOMSON SARAH C [VerfasserIn]
ALMO STEVEN C [VerfasserIn]
SEIDEL RONALD D [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-12-15, Last update posted on www.tib.eu: 2023-07-10, Last updated: 2023-07-14

Patentnummer:

AU2017266905

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA004686616